Glaukos Corporation (NYSE: GKOS) shares jumped 33.65% to close at $242.48 on October 29, 2026, gaining $61.05 from the previous close of $181.43. The stock remained unchanged in overnight trading at $242.48.
During the reported session, shares traded between $207.41 and $243.71, opening at $211.00. Trading volume reached approximately 5.41 million shares, significantly above the average volume of approximately 957,806. The company’s intraday market capitalization stood at approximately $14.30 billion.
Glaukos’ 52-week trading range was $80.90 to $243.71. Its five-year monthly beta was 0.69, while trailing earnings per share stood at negative $2.95. The one-year analyst target estimate was $223.17, below the reported closing price. The supplied data also showed a bullish Motley Fool rating.
Company Overview
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company headquartered in Aliso Viejo, California. Founded in 1998, the company develops therapies and medical devices for glaucoma, corneal disorders, and retinal diseases.
Its portfolio includes iStent and iStent inject W micro-bypass systems, designed to treat mild-to-moderate open-angle glaucoma by restoring natural aqueous humor outflow pathways. The company also offers iStent infinite for patients with glaucoma uncontrolled by prior medical and surgical therapy, and iDose TR, an intracameral procedural pharmaceutical therapy designed to reduce intraocular pressure.
Additional products include iLink, a device for treating keratoconus; iLLution, a cream-based drug formulation platform for eyelid conditions; and retinal treatment platforms addressing age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior-segment diseases.
Glaukos distributes its products to ambulatory surgery centers, hospitals, and physician private practices through direct sales, subsidiaries, and distributors.
Financial and Valuation Snapshot
Glaukos reported trailing earnings per share of negative $2.95, while its market capitalization reached approximately $14.30 billion following the share-price increase. The supplied data did not provide a trailing price-to-earnings ratio or forward dividend.
The stock’s one-year analyst target estimate of $223.17 was below its closing price of $242.48. Shares also finished close to the reported 52-week high of $243.71.
The substantial increase in trading volume indicates heightened market activity. However, the supplied screenshots do not include revenue, cash flow, debt, or detailed profitability figures needed to evaluate the company’s broader financial position.
Upcoming Earnings and Corporate Developments
Glaukos’ third-quarter 2026 earnings date was listed as October 28, 2026, with the earnings call available for replay and a transcript provided through the company’s investor information.
The supplied data does not include the detailed quarterly results or management’s guidance. Consequently, the available information does not establish which financial or operational developments may have contributed to the sharp increase in the share price.
Market Outlook
Glaukos recorded a substantial single-session gain, with shares rising more than 33% and trading volume exceeding five times the reported average. The stock also approached its 52-week high, reflecting the scale of the move.
The company’s portfolio spans glaucoma treatments, corneal devices, and retinal therapies, providing exposure to several areas of ophthalmic care. However, negative trailing earnings per share and a share price above the listed analyst target remain relevant considerations.
Investors will be watching the company’s latest earnings disclosures and management commentary for additional information on product performance, commercial progress, and financial results. The available market data alone does not establish whether the rally represents a sustained change in valuation expectations.
